This company seems to have been delisted
Reason: Acquired by AstraZeneca
Last recorded trade on: April 26, 2024
Source: https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-gracell-completed.htmlherapy%20ambition.
Reason: Acquired by AstraZeneca
Last recorded trade on: April 26, 2024
Source: https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-gracell-completed.htmlherapy%20ambition.
Gracell Biotechnologies
GRCL
$16.21
Share price
0.00%
Change (1 day)
184.37%
Change (1 year)
Categories
EPS for Gracell Biotechnologies (GRCL)
EPS in 2023 (TTM): -$1.90
According to Gracell Biotechnologies's latest financial reports the company's current EPS (TTM) is -$2.00. In 2022 the company made an earnings per share (EPS) of -$2.11 a decrease over its 2021 EPS that were of -$1.69.
EPS history for Gracell Biotechnologies from 2020 to 2023
Annual EPS
| Year | EPS | Change |
|---|---|---|
| 2023 (TTM) | -$1.90 | -9.75% |
| 2022 | -$2.11 | 24.79% |
| 2021 | -$1.69 | -6.49% |
| 2020 | -$1.80 |
EPS for similar companies or competitors
| Company | EPS | EPS differencediff. | Country |
|---|---|---|---|
 | -$3.45 | 72.38% | 🇺🇸 USA |